Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-05
2011-07-05
Nolan, Jason M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S183000
Reexamination Certificate
active
07973062
ABSTRACT:
Compounds of the thiazolidinedione family are provided and shown to be effective androgen receptor ablative agents that can be used in methods of treating or preventing cancer or precancer, including prostate cancer. Also provided are methods of treating or preventing cancer by administering a therapeutically effective amount of one of the androgen receptor ablative agents to a subject in need of such treatment.
REFERENCES:
patent: 4376777 (1983-03-01), Kawamatsu et al.
patent: 5387596 (1995-02-01), Takebayashi et al.
patent: 5801173 (1998-09-01), Lohray et al.
patent: 6046222 (2000-04-01), Atonucci et al.
patent: 6765013 (2004-07-01), Pfahl et al.
patent: 7566787 (2009-07-01), Chen
patent: 7714005 (2010-05-01), Chen et al.
patent: 2006/0252801 (2006-11-01), Chen
patent: 454501 (1991-04-01), None
patent: 2006/069186 (2006-06-01), None
patent: 2006/069217 (2006-06-01), None
Heinlein et al. Endocrine Reviews 2004, 25(2), 276-308.
Schafer et al. Drug Discovery Today 2008, 13 (21/22), 913-916.
Horig et al. Journal of Translational Medicine 2004, 2(44).
Huang et al. J. Med. Chem. 2006, 49, 4684-4689.
International Search Report and Written Opinion from PCT/US05/46454, mailed Jul. 14, 2006.
International Search Report and Written Opinion for PCT/US05/46534, mailed Mar. 14, 2008.
International Search Report and Written Opinion from PCT/US09/34650 dated Jul. 16, 2009.
Office action from U.S. Appl. No. 11/315,077 dated Jan. 2, 2009.
Amendment from U.S. Appl. No. 11/315,077 dated Mar. 30, 2009.
Office action from U.S. Appl. No. 11/315,569 dated May 19, 2008.
Amendment from U.S. Appl. No. 11/315,569 dated Nov. 19, 2008.
Notice of Allowance from U.S. Appl. No. 11/315,569 dated Mar. 24, 2009.
Altiok, et al., PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A. Genes Dev, 11: 1987-1998, 1997.
Cancer Topics [online], retrieved from the Internet Apr. 24, 2008, www.nci.nih.gov/cancertopics/druginfo/alphalist/pring?page=&keyword.
Clark et al., “Substituted dihydrobenzopyran and Dihydrobenzofuran Thiazolidine-2,4-diones as Hypoglycemic Agents”, J Med Chem vol. 34, pp. 319-325, chart 1, 1991.
Golub et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring”, Science, vol. 286, pp. 531-537, Oct. 15, 1999.
Gupta, et al., Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells. J Biol Chem, 276: 29681-29687, 2001.
Huang et al (Jan. 13, 2005), Peroxisome Proliferator-Activated Receptor y-Independent Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells, Mol Pharmacol 67: 1342-1348.
Kwon, Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists, Jun. 24, 2001, Apr. 24, 2008.
Metabolomics [online], retrieved from the Internet Apr. 24, 2008, www.en.wikipedia.org/wiki/metabolomics.
Orlinskii, “Preparative synthesis method for thiazolidine-2, 4-dione and its N-derivatives”, Pharmaceutical Chemical Journal, vol. 29, No. 2, pp. 144, 1995.
Palakurthi et al. (2001), Anticancer Effects of Thiazolidinediones are Independent of Peroxisome Proliferator-activated Receptor y and Mediated by Inhibition of Translation Initiation, Cancer Res 61: 6213-6218.
Qin et al., (2003) Peroxisome proliferator-activated receptor gamma agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor alpha in MCF-7 breast cancer cells. Cancer Res 63:958-64.
Reddy et al. (1999), Novel Antidiabetic and Hypolipedemic Agents. 5. Hydroxyl versus Benzyloxy Containing Chroman, Journal of Med Chem 42: 3265-3278.
Shiau et al. (Feb. 19, 2005), Thiazolidenediones Mediate Apoptosis in Prostate Cancer Cells in Part through Inhibition of Bcl-xL/Bcl-2 Functions Independently of PPARy.
Tontonoz, et al., Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A, 94: 237-241, 1997.
Yang et al., “Peroxisome proliferator-activated receptor γ-Independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation”, Cancer Res. 67(7), pp. 3229-3238 (2007).
Yang et al., “Pharmacological Exploitation of the Peroxisome Proliferator-Activated Receptor γ Agonist Ciglitazone to develop a novel class of Androgen Receptor-Ablative agents”, J. Med Chem, 51, pp. 2100-2107 (2008).
Yu et al., (2001) Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017-21.
Chen Ching-Shih
Wang Dasheng
Yang Jian
Calfee Halter & Griswold LLP
Nolan Jason M
The Ohio State University Research Foundation
LandOfFree
Androgen receptor-ablative agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Androgen receptor-ablative agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Androgen receptor-ablative agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2621358